Performance of Diltiazem Tablet and Multiparticulate Osmotic Formulations in the Dog
- 1 January 1990
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 07 (8) , 874-878
- https://doi.org/10.1023/a:1015925302374
Abstract
The in vivo performance of two extended-release (ER) osmotic formulations of diltiazem were evaluated in the beagle dog. Both ER formulations had similar bioavailabilities (F) as the diltiazem solution. Although F was somewhat variable following ER administration, this variability may be related to the drug entity since intra- and interanimal variability of orally administered diltiazem solutions was substantial. Deconvolution of the ER plasma diltiazem data with absorption data from the orally administered diltiazem solutions provided an estimate of the in vivo drug release from the ER formulations. The two ER formulations, designed with different in vitro release profiles, reflected these differences in vivo, with nearly identical respective in vivo and in vitro release profiles.This publication has 6 references indexed in Scilit:
- High-performance liquid chromatographic determination of diltiazem and four of its metabolites in plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1985
- Cardiovascular Effects of the Metabolites of Diltiazem in DogsJournal of Cardiovascular Pharmacology, 1985
- Quantitation of Diltiazem and Desacetyldiltiazem in Dog Plasma by High-Performance Liquid ChromatographyJournal of Pharmaceutical Sciences, 1984
- Pharmacokinetic and pharmacodynamic effects of diltiazemThe American Journal of Cardiology, 1983
- Pharmacokinetics of diltiazem in selected animal species and human beingsThe American Journal of Cardiology, 1982
- Do you need a pharmacokinetic model, and, if so, which one?Journal of Pharmacokinetics and Biopharmaceutics, 1975